The practical part comes first, before any of the regulatory story: sudden loss of vision, or vision that is rapidly worsening, is an urgent symptom under any regulator's reading, and it belongs with a clinician the same day. Not after the next dose, and not after finishing this article. That instruction appears in the European guidance this article is about, and nothing in the US position contradicts it either. Everything else here is context for that sentence.
The context is genuinely interesting, which is why it gets an article. On the question of one rare eye condition and the semaglutide medicines, Ozempic, Rybelsus and Wegovy, the European and US labels now say different things. European regulators list the condition as a very rare side effect; the US labels do not mention it at all. Both positions are defensible, and understanding why they differ says a lot about what a drug label actually is.
The condition: what NAION is
NAION stands for non-arteritic anterior ischemic optic neuropathy. It affects the optic nerve, and its signature is sudden complete or partial loss of vision in one eye, or more rarely both. It is rare in the general population, which matters enormously for everything that follows, because the meaning of any risk figure about a rare condition depends on how rare it was to begin with.
Two features of NAION shape how regulators handle it. It arrives suddenly, which is why the patient instruction attached to it is about urgency. And it is uncommon enough that even a meaningful change in its frequency among medicine users still amounts to a small number of affected people, which is what the arithmetic in a later section shows.
What the European regulator concluded
On 6 June 2025, the Pharmacovigilance Risk Assessment Committee of the European Medicines Agency, usually abbreviated PRAC, published its conclusion: NAION is a very rare side effect of the semaglutide medicines Ozempic, Rybelsus and Wegovy. In the frequency language of European product information, very rare means a side effect that may affect up to 1 in 10,000 people.
The committee's basis was spelled out. Results from several large epidemiological studies, in its words, suggest that exposure to semaglutide in adults with type 2 diabetes is associated with an approximately two-fold increase in the risk of developing NAION compared with people not taking the medicine. The committee also gave the figure that matters more than that relative one, and it is worth quoting exactly: this corresponds to approximately one additional case of NAION per 10,000 person-years of treatment. PRAC recommended that the product information for these medicines be updated to list NAION with a frequency of very rare.
The announcement carried a patient instruction with it. If patients experience a sudden loss of vision or rapidly worsening eyesight during treatment, they should contact their doctor without delay, and if NAION is confirmed, treatment with semaglutide should be stopped. Those are the European regulator's words, reported here as such. Note what they are: an instruction about symptoms and an instruction to clinicians about what follows a confirmed diagnosis, not a reason for anyone to pre-empt either step.
What the US labels say
The current US prescribing information for Ozempic, Wegovy, Zepbound and Mounjaro contains no mention of NAION, and no mention of ischemic optic neuropathy of any kind. That reflects the full label text rather than a summary. The US labels are simply silent on the condition.
Silence on NAION is not silence on eyes, though. The US labels carry a different eye warning, titled Diabetic Retinopathy Complications. The Ozempic label states that it has been reported in a clinical trial and that patients with a history of diabetic retinopathy should be monitored, at section 5.3; Wegovy and Zepbound carry the equivalent language for patients with type 2 diabetes at section 5.8, and Mounjaro at 5.7. Separately, Mounjaro's Patient Counseling section instructs that patients be informed to contact their healthcare provider if changes in vision are experienced during treatment. So a US reader looking for eye information on a GLP-1 label will find a warning, just not the European one.
GLP 1 Tracker AppA private log of doses, dates and side effect notes, on your phone only, ready if a conversation with a clinician ever needs the timeline.
Get the app
Two-fold, and one case per 10,000 person-years
The heart of this subject is the pair of numbers in the European conclusion, and the discipline of always giving them together. A two-fold increase in risk sounds enormous. Doubled is doubled. But the doubling applies to a condition that is rare to begin with, and when PRAC did that arithmetic it landed on approximately one additional case of NAION per 10,000 person-years of treatment. That is what the doubling amounts to: one extra case, per 10,000 people treated for a year.
Neither number is a lie, and neither one alone is honest. The relative figure is what the studies observed; the absolute figure is what it means at the population level. This site has made the same point about cardiovascular trial percentages, and the fuller walkthrough of relative versus absolute risk lives in GLP-1s and the Heart: What the Outcome Trials Showed. The habit worth building is simple: whenever a doubling or a percentage appears in a health headline, ask what the underlying rate was, because the answer is where the real meaning sits.
And a further caution that belongs with both numbers: these are population figures from epidemiological studies in adults with type 2 diabetes. They describe groups. They do not describe any individual reader's eyes, and no article, including this one, can tell a person what their own visual symptom means. That question has exactly one destination, which is a clinician, reached without delay.
Why two regulators can differ
Two regulators looked at overlapping evidence and made different labeling decisions, and the temptation is to decide which one is right. This article will not do that, because the disagreement is less dramatic than it looks. A labeling decision is a judgment about what patients and prescribers on one continent need told, made by an institution with its own procedures, thresholds and history with a medicine class. Two careful institutions can weigh the same studies and land in different places on whether a label should carry a rare event.
It is worth saying plainly what this divergence is not. It is not evidence that one regulator is asleep, and it is not evidence that the other is alarmist. Readers who follow this class will notice that the US and European labels have diverged before and converged before, on other questions, and nothing in this article predicts which way the NAION question settles. What the divergence does show is where the certain part ends: sudden vision loss goes to a clinician immediately, on everyone's reading, and everything beyond that is a judgment that belongs to institutions and clinicians rather than to a reader alone.
Keeping the two eye subjects separate
Because the US labels do carry an eye warning, a reader who hears about the European one can easily conflate the two, so the distinction deserves its own paragraph. Diabetic retinopathy complications, the US warning, are about people who already have diabetic eye disease and whose glucose control then improves rapidly; the label's instruction is about monitoring that existing disease. NAION, the European listing, is about a sudden event affecting the optic nerve, listed as very rare, with an instruction about urgency. Different condition, different population, different mechanism, different label.
What connects them is only this: both routes run through a clinician who can actually examine an eye. A person with known retinopathy has a monitoring relationship with an eye clinician already, and these medicines change the background against which that monitoring happens, which is one more reason the whole medication list belongs in that conversation. Lab work and monitoring of the kind these medicines involve has its own overview in Blood Work on a GLP-1: Numbers Worth Keeping. The broader pattern of this class carrying serious boxed warnings, including the thyroid warning every label shares, is read carefully in The Boxed Warning on Your GLP-1 Label, Explained. The eyes have their own place in that pattern, and the honest summary is the one this article opened with: under either regulator's label, a sudden change in vision is not a reading matter, it is an appointment matter, the same day.
Frequently asked questions
Can GLP-1 medications cause sudden vision loss?
European regulators concluded that a rare condition called NAION, non-arteritic anterior ischemic optic neuropathy, which causes sudden complete or partial loss of vision in one eye, is a very rare side effect of the semaglutide medicines Ozempic, Rybelsus and Wegovy. The US labels do not mention it. Whatever a reader makes of the divergence, sudden vision loss or rapidly worsening eyesight is an urgent symptom under any regulator's reading and belongs with a clinician without delay.
What did the EMA conclude about semaglutide and NAION?
On 6 June 2025 the EMA's Pharmacovigilance Risk Assessment Committee concluded that NAION is a very rare side effect of Ozempic, Rybelsus and Wegovy, meaning it may affect up to 1 in 10,000 people taking semaglutide. The basis was several large epidemiological studies suggesting an approximately two-fold increase in risk in adults with type 2 diabetes, corresponding to roughly one additional case per 10,000 person-years of treatment, and the product information was updated accordingly.
Why does the US label not mention NAION?
The current Ozempic, Wegovy, Zepbound and Mounjaro labels contain no mention of NAION or of ischemic optic neuropathy of any kind. Regulators on both sides of the Atlantic looked at overlapping evidence and made different labeling decisions, which is ordinary: a labeling decision is a judgment about what patients and prescribers need told, not a vote on what is true. Nothing here implies either agency is wrong.
Is NAION the same as the diabetic retinopathy warning on the US label?
No, they are different subjects and should not be blurred together. NAION affects the optic nerve and causes sudden vision loss. The diabetic retinopathy complications warning on the US labels is about existing eye disease in people with diabetes and rapid improvement in glucose control; Ozempic carries it at section 5.3, Wegovy and Zepbound at 5.8, and Mounjaro at 5.7. One concerns a rare sudden event; the other concerns monitoring in known retinopathy.
What should I do if my vision changes suddenly on a GLP-1?
Contact a clinician without delay. The EMA's instruction is exactly that: sudden loss of vision or rapidly worsening eyesight during treatment should be reported to a doctor without delay, and if NAION is confirmed, treatment with semaglutide should be stopped. Whether any individual's symptom is NAION is a diagnosis only a clinician can make, and no article should stand between a symptom and an appointment.